Current position

Fidelity Investments’s Cytokinetics Inc (CYTK) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

FMR LLCVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2021Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares13.36MHighest verified quarter-end share count
Quarters reported12Verified quarters with shares above zero
What happened?

FMR LLC first reported Cytokinetics Inc in Q3 2021. The reported position was increased and reduced across later filings. FMR LLC currently reports 5.03M shares. The latest verified filing showed: Sold 53.1% of the position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Sold 53.1% of the position−5.69M shares · 5.03M shares remained
Filing context

Quarter-end price $85.19

Q4 2025
Sold 2.2% of the position−283.90K shares · 12.81M shares remained
Filing context

Quarter-end price $63.54

Q3 2025
Bought 16.2% more+1.82M shares · 13.09M shares reported after the change
Filing context

Quarter-end price $54.96

Q4 2024
Sold 10.7% of the position−1.30M shares · 10.79M shares remained
Filing context

Quarter-end price $47.04

Q2 2024
Bought 5.7% more+621.99K shares · 11.52M shares reported after the change
Filing context

Quarter-end price $54.18

Q1 2024
Sold 16.2% of the position−2.11M shares · 10.90M shares remained
Filing context

Quarter-end price $70.11

Portfolio importance

How important is Cytokinetics Inc in FMR LLC’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.0%Q2 2026
Current rank#615of 5572 reported positions
Peak portfolio weight0.1%Q4 2023
Best historical rank#211Q4 2023
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$68.782026-09-18

Market context only; not an investor transaction price.

Latest filing quarter-end price$85.19Q2 2026

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-13
Open SEC filing ↗

Coverage is bounded to Fidelity’s top reported positions and material events rather than every security in each Form 13F. The consolidated FMR LLC filing includes multiple Fidelity investment managers. Source filings may contain additional securities, and 13F filings do not reveal exact trade dates or execution prices.